Company2021-05-20T15:14:21+08:00

ABOUT US

SINOMED is a global company engaged in patient-focused medical innovations for interventional medicine. We offer pioneering solutions for treating coronary, neurovascular and structural heart disease. We strive to combine the ingenuity of people with the power of technology to achieve new victories against cardiovascular disease.

SINOMED was founded in 2007 as a startup company searching for a way to improve the common coronary stent. Today, the company is a publicly traded company on the Shanghai STAR market and one of the leaders in the Chinese coronary stent market. The company’s headquarters is located in Tianjin, China, with a 6,000 m² class 10,000 cleanroom for manufacturing, quality control and development. Since its humble beginnings, SINOMED has worked closely with industry thought-leaders expanding its product offering to include a portfolio of coronary stents and balloons, as well as neurovascular and structural heart disease products.

We are devoted to becoming a global leader in medical devices, focusing on supporting healthcare professionals in their daily efforts to improve the lives of patients. We do this by continuing to evolve our technologies, focusing on quality in everything we do and striving to secure global access to our devices. At SINOMED, we are creating innovations for health.

MISSION

Through our efforts, we aim to expose more patients to the benefits of our medical innovations; increasing patient longevity and quality of life.

VISION

To become one of the global market leaders in providing valued medical devices in the fields in which we are active. 

IN THE EYES OF THE EXPERTS

Dr. Martin B.Leon

M.D., FACC, Founder of Transcatheter Cardiovascular Therapeutics Conference, Chairman of SINOMED PIONEER Ⅲ Clinical Trial

“SINOMED is the first Chinese company to conduct such a large-scale clinical study of coronary stents in the US. The device is not an imitated technology, but technical innovation. I believe that in the future, it will bring tangible benefits to American patients.”

Dr. Patrick W. Serruys

M.D., FACC
Co-founder of EuroPCR Conference
PI of SINOMED PIONEERⅠClinical Trial

“Not only is the company growing locally, SINOMED is also expanding into the international market. I believe that SINOMED will build an Asian brand with international influence and innovation.”

Dr. Shigeru Saito

M.D., Chairman of NPO International TRI Network, First Doctors Perform Radial Artery Cardiac Interventional Therapy, PI of PIONEER Ⅲ Japan Clinical Trial

“As the first Chinese stent company to carry out large-scale clinical studies in Japan, I was deeply impressed by the rigorous and pragmatic spirit of SINOMED.”

Dr. Renu Virmani

M.D., Pathologist, President of CVPath, Leader of BuMA and Supreme HT Animal Studies

“SINOMED is not a me-too company. It brought innovation from China to the world.”

Dr. Junbo Ge

M.D., Academician of Chinese Academy of Science, Former President of China Society of Cardiology, PI of SINOMED PIONEER III Clinical Trial

“SINOMED truly lives their claim of ‘Innovation for Health’ by providing quality products for coronary, structural and neurological interventions in China and around the world.”

Dr. Yong Huo

M.D., FACC, Former President of China Society of Cardiology, PI of BuMA’s PANDA II Clinical Trial

“Trying to solve the main problem of DES – the late or very late in-stent thrombosis – by the achievement on endothelialization, BuMA® could be a milestone on the way of the development and innovation of DES not only in China, but in the world. ”